August Troendle Sells 13,995 Shares of Medpace (NASDAQ:MEDP) Stock

Posted by Geri Gentry on Aug 25th, 2026

Medpace Holdings, Inc. (NASDAQ:MEDP – Get Free Report) CEO August Troendle sold 13,995 shares of Medpace stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $624.45, for a total transaction of $8,739,177.75. Following the completion of the transaction, the chief executive officer owned 547,200 shares of the company’s stock, valued at $341,699,040. The trade was a 2.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Medpace Trading Down 1.1%

Shares of NASDAQ MEDP traded down $6.66 during midday trading on Tuesday, hitting $613.37. The company’s stock had a trading volume of 246,088 shares, compared to its average volume of 346,263. The stock has a fifty day moving average price of $553.21 and a 200 day moving average price of $492.40. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90. The firm has a market capitalization of $17.12 billion, a price-to-earnings ratio of 35.95, a P/E/G ratio of 2.77 and a beta of 1.15.

Medpace (NASDAQ:MEDP – Get Free Report) last released its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. During the same period last year, the firm earned $3.10 EPS. Medpace’s revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities research analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently issued reports on MEDP shares. BMO Capital Markets increased their price objective on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a report on Friday, July 24th. Leerink Partners set a $620.00 target price on Medpace in a report on Thursday, July 23rd. Royal Bank Of Canada upped their price target on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Mizuho increased their price target on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Finally, Barclays set a $600.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Three equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $584.18.

Check Out Our Latest Stock Report on Medpace

Hedge Funds Weigh In On Medpace

A number of institutional investors have recently added to or reduced their stakes in the business. Johnson Financial Group Inc. bought a new stake in shares of Medpace during the 2nd quarter valued at about $27,000. Elyxium Wealth LLC purchased a new position in shares of Medpace during the fourth quarter worth about $30,000. Jones Financial Companies Lllp bought a new position in shares of Medpace in the second quarter worth approximately $30,000. Allied Private Wealth LLC bought a new position in shares of Medpace in the second quarter worth approximately $31,000. Finally, Kilter Group LLC purchased a new stake in Medpace in the second quarter valued at approximately $31,000. 77.98% of the stock is currently owned by institutional investors.

About Medpace

(Get Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.